Status:
UNKNOWN
A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients
Lead Sponsor:
Avera McKennan Hospital & University Health Center
Collaborating Sponsors:
Cellworks Group Inc.
Conditions:
Pan-cancer
Eligibility:
All Genders
Brief Summary
The purpose of this study is to determine the benefit of Cellworks Singula™ and Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indic...
Eligibility Criteria
Inclusion
- Have any stage of cancer for the indications listed at: https://cellworks.life/mycare101 Patients are eligible at any stage of disease.
- Expected to be alive 6 months or more
- Requirements for NGS testing (e.g., panel or whole-exome sequencing): NGS testing has been ordered from or performed by one or more vendors specified at: https://cellworks.life/mycare101 . NGS reports must be ordered or performed within the last 90 days. Cellworks will accept all NGS input formats available, including PDF, VCF, BAM, and FastQ.
- Requirements for additional laboratory testing If Hematological Indication, Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered If Acute Myeloid Leukemia (AML), FLT3-itd testing has been ordered If Indication is a form of Brain Cancer (e.g., glioblastoma), Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered and MGMT Methylation test has been ordered
Exclusion
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
730 Patients enrolled
Trial Details
Trial ID
NCT05308784
Start Date
January 1 2022
End Date
December 31 2025
Last Update
July 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Avera McKennan
Sioux Falls, South Dakota, United States, 57105